The startup develops gene delivery and cell engineering technology to enhance the efficacy of immune cells in targeting cancer cells. This approach enables the creation of cost-effective and safe treatments, improving the quality of care for cancer patients.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments, such as chemotherapy and radiation, often have systemic toxicities and lack the specificity needed to target cancer cells effectively, leading to significant side effects and limited efficacy. Engineering immune cells to target tumors more precisely is challenging due to difficulties in efficient and safe gene delivery.
Solution
This startup is developing a novel gene delivery and cell engineering platform to enhance the ability of immune cells to recognize and destroy cancer cells. Their technology aims to improve the safety and efficacy of cell-based cancer therapies by enabling precise modification of immune cells with minimal off-target effects. By optimizing gene delivery methods, they seek to create more potent and targeted immunotherapies that can overcome the limitations of existing treatments. This approach has the potential to reduce the toxic side effects associated with conventional cancer therapies while improving patient outcomes.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinical centers involved in the development and application of cell-based immunotherapies for cancer treatment.
Features
- Proprietary gene delivery technology for efficient and specific modification of immune cells
- Cell engineering platform to enhance the targeting capabilities of immune cells against cancer
- Focus on improving the safety profile of cell-based cancer therapies